Zydus Lifesciences Ltd share Price Today

Zydus is a leading pharma company with family pedigree having a presence in domestic branded formulations, US generics and is in the process of repurposing itself into niche areas of specialty pharmaceuticals, biosimilars and vaccines.

• Q3FY23 revenue break-up – US: 46.3%, India: 29.6%, Wellness: 9.9%, Europe & emerging markets including countries in LatAm, Asia Pacific & Africa: 14.2%
• Zydus is the fourth largest pharma company in India with 14 brands among Top 300 pharma brands in India and nine with ₹ 100 crore+ sales

Zydus delivered good set of numbers, which beat our estimates.

• Revenues grew 19.8% YoY at ₹ 4362 crore
• EBITDA grew 27.2% YoY to ₹ 956 crore. EBITDA margins improved 127 bps YoY to 21.9%
• Adjusted net profit rose 22.8% YoY to ₹ 622.5 crore

Pharmaceuticals company Zydus Lifesciences announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

• Revenue from operations was Rs 55,338 million, up 10% over last year.
• Research & Development (R&D) investments for the quarter stood at Rs 3,516 million (6.4% of revenues).
• EBITDA for the quarter was Rs 16,305 million, up 30% YoY. EBITDA margin for the quarter stood at 29.5%, an improvement of 440 bps on a YoY basis.
• Net Profit for the quarter was Rs 11,823 million, up 299% YoY.
• Capex (organic) for the quarter was Rs 2,126 million

FY24 Financial Highlights:

• Revenue from operations was Rs 1,95,474 million, up 13% over last year.
• Research & Development (R&D) investments stood at Rs 13,096 million (6.7% of revenues).
• EBITDA was Rs 53,843 million, up 40% YoY. EBITDA margin stood at 27.5%, an improvement of 510 bps over the previous year.
• Net Profit was Rs 38,595 million, up 97% YoY.
• Capex (organic) for the year was Rs 8,628 million.
• Net Debt to Equity ratio as on 31st March, 2024 was -0.04x while Net Debt to EBITDA stood at -0.16x at the end of March, 2024. Net Cash (negative Net Debt) as on March 31st, 2024 was Rs 8,561 million. 

Dr. Sharvil Patel, Managing Director, said, "We are happy to close the year on a strong note, driven by robust performance across our businesses. Our relentless focus on patient centricity, operational efficiency, strategic investments, and execution of our diversified product portfolio continues to pay off, resulting in a significant improvement in profitability as well. We aspire to sustain strong performance in fiscal year 2024-25 with strong revenue growth and strive to improve EBITDA margins further from FY24 levels. This strong performance is a testament to our commitment to creating long-term value for our stakeholders, and we are wellpositioned for future growth and innovation"

Result PDF